Sara Kenkare Mitra Alector, Inc. (ALEC) insider trading activity

Sara Kenkare Mitra is President and Head of R&D of Alector, Inc.. Currently has a direct ownership of 536,142 shares of ALEC, which is worth approximately $691,623. The most recent transaction as insider was on Mar 03, 2025, when has been sold 29,073 shares (Common Stock) at a price of $1.47 per share, resulting in proceeds of $42,737. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 536K

5.14% 3M change

68.15% 12M change

Total Value Held $691,623

Sara Kenkare-Mitra Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2025	SELL Open market or private sale	$42,737 $1.47 p/Share	29,073 Reduced 5.14%	536,142 Common Stock
Dec 02 2024	SELL Open market or private sale	$66,780 $2.52 p/Share	26,500 Reduced 4.48%	565,215 Common Stock
Oct 01 2024	BUY Grant, award, or other acquisition	-	300,000 Added 33.64%	591,715 Common Stock
Sep 03 2024	SELL Open market or private sale	$67,958 $4.88 p/Share	13,926 Reduced 4.56%	291,715 Common Stock
Jun 03 2024	SELL Open market or private sale	$63,388 $4.8 p/Share	13,206 Reduced 4.14%	305,641 Common Stock
Mar 04 2024	SELL Open market or private sale	$70,369 $6.92 p/Share	10,169 Reduced 3.09%	318,847 Common Stock
Dec 04 2023	SELL Open market or private sale	$69,605 $5.56 p/Share	12,519 Reduced 3.67%	329,016 Common Stock
Oct 01 2023	BUY Grant, award, or other acquisition	-	163,600 Added 32.39%	341,535 Common Stock
Sep 05 2023	SELL Open market or private sale	$32,250 $5.19 p/Share	6,214 Reduced 3.37%	177,935 Common Stock
Jun 02 2023	SELL Open market or private sale	$28,234 $6.9 p/Share	4,092 Reduced 2.17%	184,149 Common Stock
Mar 02 2023	SELL Open market or private sale	$84,231 $8.32 p/Share	10,124 Reduced 5.1%	188,241 Common Stock
Oct 01 2022	BUY Grant, award, or other acquisition	-	80,365 Added 28.83%	198,365 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	118,000 Added 50.0%	118,000 Common Stock

Also insider at

UNCY

Unicycive Therapeutics, Inc. Healthcare

Director